drugset / Trial / NCT03276156
Apatinib in Combination With S-1 as Second-Line Treatment in Patients With Advanced Gastric Cancer
NaSingle-groupOpen-labelTreatment
Summary
The purpose of this study is to determine the maximum tolerated dose (MTD)and safety of Apatinib combined with S-1 as Second-line therapy for patients with advanced gastric or gastroesophageal junction adenocarcinoma.
Timeline
- Start
- 2016-02-23
- Primary completion
- 2018-02-22
- Completion
- 2018-02-22
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Rivoceranib | Small molecule | 425 mg | Oral |
| Subject | Rivoceranib | Small molecule | 500 mg | Oral |
| Subject | Rivoceranib | Small molecule | 675 mg | Oral |
| Subject | Rivoceranib | Small molecule | 750 mg | Oral |
| Subject | S-1 | Small molecule | 80 mg | Oral |
| Subject | S-1 | Small molecule | 120 mg | Oral |